Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial

Viviana Galimberti, Bernard F Cole, Stefano Zurrida, Giuseppe Viale, Alberto Luini, Paolo Veronesi, Paola Baratella, Camelia Chifu, Manuela Sargenti, Mattia Intra, Oreste Gentilini, Mauro G Mastropasqua, Giovanni Mazzarol, Samuele Massarut, Jean-Rémi Garbay, Janez Zgajnar, Hanne Galatius, Angelo Recalcati, David Littlejohn, Monika BamertMarco Colleoni, Karen N Price, Meredith M Regan, Aron Goldhirsch, Alan S Coates, Richard D Gelber, Umberto Veronesi, International Breast Cancer Study Group Trial 23-01 investigators

986 Citationer (Scopus)

Abstract

For patients with breast cancer and metastases in the sentinel nodes, axillary dissection has been standard treatment. However, for patients with limited sentinel-node involvement, axillary dissection might be overtreatment. We designed IBCSG trial 23-01 to determine whether no axillary dissection was non-inferior to axillary dissection in patients with one or more micrometastatic (≤2 mm) sentinel nodes and tumour of maximum 5 cm.
OriginalsprogEngelsk
TidsskriftThe Lancet Oncology
Vol/bind14
Udgave nummer4
Sider (fra-til)297-305
Antal sider9
ISSN1470-2045
DOI
StatusUdgivet - apr. 2013

Fingeraftryk

Dyk ned i forskningsemnerne om 'Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial'. Sammen danner de et unikt fingeraftryk.

Citationsformater